IGC Pharma (IGC) Stock: Buy, Sell, or Hold?
IGC - IGC Pharma, Inc.
$0.19
-0.01 (-7.13%)
▼
5d:
-24.8%
30d:
-31.48%
90d:
-24.52%
WAIT
LOW Confidence
Analysis Updated: Oct 30, 2026 12:00 AM ET
Earnings: Nov 13, 2026
10d
Get Alerted When IGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IGC is down 24.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IGC is down 24.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IGC is currently trading at $0.18, which is considered oversold relative to its 30-day fair value range of $0.24 to $0.28.
Technical Outlook: Technically, IGC is in a uptrend. Immediate support is located at $0.08, while resistance sits at $0.27. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: IGC scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+3143.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IGC is in a uptrend. Immediate support is located at $0.08, while resistance sits at $0.27. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: IGC scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+3143.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.24 -
$0.28
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.1%)
- BULLISH: Trading 3143.2% below Wall St target ($6.00)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.24 -
$0.28
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.08
Resistance Level
$0.27
Current Trend
Uptrend
Technical data as of
Oct 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.06
Wall Street Target
$6.00
(+3143.2%)
Revenue Growth (YoY)
-19.2%
Share & Embed Analysis
Last updated: November 01, 2026 7:55 PM ET
Data refreshes hourly during market hours. Next update: 8:55 PM
Data refreshes hourly during market hours. Next update: 8:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IGC showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$924 | 35 SELL |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
21 analysts |
$650 | 39 SELL |
|
NAMS
NewAmsterdam Pharma Comp… |
STRONG BUY
16 analysts |
$50 | 50 HOLD |
|
CADL
Candel Therapeutics Inc |
STRONG BUY
10 analysts |
$22 | 69 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 44 HOLD |
